|
Market Closed -
Swiss Exchange
12:30:30 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 411.20 CHF | +0.44% |
|
+3.47% | +22.67% |
| 10-30 | HEALTH ROUNDS-Rise in US colon cancer rates not limited to young adults, analysis finds | RE |
| 10-30 | Sanofi teases appetite for larger deals, lifts 2026 growth targets under new CEO Garijo | RE |
Company Valuation: Roche Holding AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 306,810 | 239,812 | 197,073 | 205,191 | 262,098 | 322,248 | - | - |
| Change | - | -21.84% | -17.82% | 4.12% | 27.73% | 22.95% | - | - |
| Enterprise Value (EV) 1 | 324,977 | 255,396 | 215,772 | 222,528 | 278,258 | 333,621 | 327,100 | 318,665 |
| Change | - | -21.41% | -15.51% | 3.13% | 25.04% | 19.9% | -1.95% | -2.58% |
| P/E | 23.4x | 18.9x | 17.1x | 24.8x | 20.5x | 21.7x | 19.5x | 17.9x |
| PBR | 13.2x | 8.29x | 5.91x | 5.67x | 7.8x | 7.87x | 6.5x | 5.47x |
| PEG | - | -3.69x | -2.48x | -0.9x | 0.4x | 1.4x | 1.7x | 2.03x |
| Capitalization / Revenue | 4.89x | 3.79x | 3.36x | 3.39x | 4.26x | 5.09x | 4.87x | 4.64x |
| EV / Revenue | 5.17x | 4.04x | 3.67x | 3.68x | 4.52x | 5.27x | 4.95x | 4.59x |
| EV / EBITDA | 13.2x | 10.2x | 9.82x | 9.45x | 11.3x | 13.1x | 11.9x | 10.9x |
| EV / EBIT | 14.8x | 11.5x | 11.2x | 10.7x | 12.7x | 14.5x | 13.3x | 12.2x |
| EV / FCF | 20.7x | 19.6x | 19.1x | 14.5x | 23.6x | 20.6x | 19.7x | 17.7x |
| FCF Yield | 4.83% | 5.11% | 5.23% | 6.89% | 4.24% | 4.84% | 5.07% | 5.65% |
| Dividend per Share 2 | 9.3 | 9.5 | 9.6 | 9.7 | 9.8 | 10.02 | 10.28 | 10.58 |
| Rate of return | 2.45% | 3.27% | 3.93% | 3.8% | 2.99% | 2.48% | 2.55% | 2.62% |
| EPS 2 | 16.2 | 15.37 | 14.31 | 10.31 | 16.04 | 18.56 | 20.73 | 22.55 |
| Distribution rate | 57.4% | 61.8% | 67.1% | 94.1% | 61.1% | 54% | 49.6% | 46.9% |
| Net sales 1 | 62,801 | 63,281 | 58,716 | 60,495 | 61,516 | 63,262 | 66,145 | 69,441 |
| EBITDA 1 | 24,692 | 25,015 | 21,976 | 23,538 | 24,608 | 25,423 | 27,489 | 29,205 |
| EBIT 1 | 21,897 | 22,173 | 19,240 | 20,823 | 21,833 | 22,977 | 24,649 | 26,202 |
| Net income 1 | 13,930 | 12,421 | 11,498 | 8,277 | 12,880 | 14,824 | 16,575 | 17,810 |
| Net Debt 1 | 18,167 | 15,584 | 18,699 | 17,337 | 16,160 | 11,373 | 4,852 | -3,583 |
| Reference price 2 | 379.10 | 290.50 | 244.50 | 255.50 | 328.20 | 403.40 | 403.40 | 403.40 |
| Nbr of stocks (in thousands) | 800,952 | 800,579 | 798,652 | 796,789 | 796,317 | 796,766 | - | - |
| Announcement Date | 2/3/22 | 2/2/23 | 2/1/24 | 1/30/25 | 1/29/26 | - | - | - |
1CHF in Million2CHF
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 41.54x | 14.06x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 38.61x | 8.62x | 17.83x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 109.15x | 6.06x | 25.73x | 2.28% | 369B | |
| 23.19x | 5.97x | 14.41x | 2.71% | 307B | |
| 24.47x | 4.9x | 13.63x | 1.77% | 290B | |
| 29.56x | 7.53x | 13.48x | 2.16% | 252B | |
| -49.1x | 7.47x | 29.35x | 1.93% | 212B | |
| Average | 31.02x | 7.40x | 19.73x | 2.01% | 473.55B | |
| Weighted average by Cap. | 37.29x | 8.84x | 21.96x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROP Stock
- RO Stock
- Valuation Roche Holding AG
Select your edition
All financial news and data tailored to specific country editions
